Stopped: Development Plan Amended
This is a multi-center, double-blind, randomized, placebo-controlled study to determine the safety, tolerability, and pharmacodynamics of SDI-118 in a once daily (QD) dosing regimen on male and female study participants reporting with cogntive decline and who in remission from depression.
Age range
25 Years – 55 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Number of participants with Adverse Events (AEs)
Timeframe: 17 days
Number of participants with laboratory value abnormalities and/or adverse events (AEs)
Timeframe: 17 days
Number of participants with vital sign abnormalities and/or adverse events (AEs)
Timeframe: 17 days
Number of participants with routine 12 lead electrocardiogram (ECG) abnormalities and/or Adverse Events (AEs)
Timeframe: 17 days
Number of participants with C-SSRS abnormalities and/or Adverse Events (AEs)
Timeframe: 17 days
Number of participants with routine physical examination abnormalities and/or Adverse Events (AEs)
Timeframe: 17 days
Number of participants with Changes in the Cogstate Brief Battery, including abnormalities and/or Adverse Events (AEs)
Timeframe: 17 days
Number of participants with Changes in the Digital Symbol Substitution Test, including abnormalities and/or Adverse Events (AEs)
Timeframe: 17 days
Number of participants with Changes in the Controlled Oral Word Association Test, including abnormalities and/or Adverse Events (AEs)
Timeframe: 17 days
Number of participants with Changes in the Category Fluency Test, including abnormalities and/or Adverse Events (AEs)
Timeframe: 17 days